Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tabitha Smith

Nurse Practitioner, Family Woodbury, TN Nurse Practitioner

NPI 1003112277 CMS profile 11175071

89 Mears Drive, Woodbury, TN 37190

Open in the dashboard

General payments

$8,539

427 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tabitha Smith of Woodbury, TN is reported in the CMS Open Payments database as having received $8,539 across 427 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,846 126
2024 General $1,647 82
2023 General $1,515 79
2022 General $1,243 66
2021 General $1,288 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tabitha Smith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Tabitha Smith were reported at $2,846. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Tabitha Smith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,288 $124 $35–$379 $132
2022 $1,243 $141 $44–$430 $149
2023 $1,515 $154 $49–$476 $160
2024 $1,647 $165 $51–$504 $164
2025 $2,846 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,349 59 payments
  2. Otsuka America Pharmaceutical, Inc. $1,046 60 payments
  3. Novo Nordisk Inc $908 48 payments
  4. Amgen Inc. $705 45 payments
  5. AstraZeneca Pharmaceuticals LP $673 17 payments
  6. Axsome Therapeutics, Inc. $434 19 payments
  7. ITI, Inc. $303 15 payments
  8. Corcept Therapeutics $232 12 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $215 13 payments
  10. Lundbeck LLC $213 9 payments
  11. Other $2,462 130 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,440 426 payments
  2. Education $99 1 payment
Products named General payments · program years 2021–2025
  1. REXULTI $1,046 60 payments
  2. Otezla $641 41 payments
  3. RYBELSUS $506 26 payments
  4. Repatha $470 28 payments
  5. Auvelity $434 19 payments
  6. FARXIGA $414 10 payments
  7. Ozempic $369 24 payments
  8. VRAYLAR Neuroscience $329 21 payments
  9. XIFAXAN $282 16 payments
  10. VRAYLAR Neuroscience $277 8 payments
  11. Other $5,703 302 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 138 drugs

Part D claims

7,045

Median for Nurse Practitioner: 389

Drug cost

$1,211,977

Median for Nurse Practitioner: $21,885

Branded share of claims

32.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 102 $132,504
Rexulti Brexpiprazole Brand 71 $132,165
Mounjaro Tirzepatide Brand 83 $111,410
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 58 $63,225
Eliquis Apixaban Brand 59 $57,130
Trulicity Dulaglutide Brand 27 $55,796
Farxiga Dapagliflozin Propanediol Brand 55 $54,762
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 42 $54,577
Xarelto Rivaroxaban Brand 47 $53,130
Jardiance Empagliflozin Brand 40 $50,447

The 10 drugs with the highest cost, of 138 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$49,872

Of which drugs: $27

Medicare patients

149

Average age 71

Services billed

1,252

86 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 48%
Diabetes 42%
Depression 31%
Chronic kidney disease 24%
COPD 16%
Ischemic heart disease 15%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $216
  • Lundbeck LLC $81
$298 71 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $137
$137 55 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $112
$112 30 —
VRAYLAR
  • AbbVie, Inc. $98
$98 14 —
Otezla
  • Amgen Inc. $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

427 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record